Aileron Therapeutics Return On Asset vs. Price To Earning

ALRN Stock  USD 2.47  0.11  4.26%   
Based on Aileron Therapeutics' profitability indicators, Aileron Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Aileron Therapeutics' ability to earn profits and add value for shareholders. As of the 24th of November 2024, Price To Sales Ratio is likely to drop to 0.14. In addition to that, EV To Sales is likely to drop to -0.25. At this time, Aileron Therapeutics' Total Other Income Expense Net is very stable compared to the past year. As of the 24th of November 2024, Income Tax Expense is likely to grow to about 974.4 K, while Accumulated Other Comprehensive Income is likely to drop (66.2 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.360.41
Fairly Down
Slightly volatile
Net Profit Margin0.00690.0078
Fairly Down
Slightly volatile
Operating Profit Margin0.120.13
Significantly Down
Slightly volatile
Pretax Profit Margin0.120.13
Significantly Down
Slightly volatile
For Aileron Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aileron Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aileron Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aileron Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aileron Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.88)
Return On Assets
(0.26)
Return On Equity
(0.44)
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Aileron Therapeutics Price To Earning vs. Return On Asset Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Aileron Therapeutics's current stock value. Our valuation model uses many indicators to compare Aileron Therapeutics value to that of its competitors to determine the firm's financial worth.
Aileron Therapeutics is rated fifth in return on asset category among its peers. It is rated third in price to earning category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aileron Therapeutics' earnings, one of the primary drivers of an investment's value.

Aileron Price To Earning vs. Return On Asset

Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Aileron Therapeutics

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.26
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Aileron Therapeutics

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
(0.31) X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Aileron Price To Earning Comparison

Aileron Therapeutics is currently under evaluation in price to earning category among its peers.

Aileron Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Aileron Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aileron Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Aileron Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Aileron Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-63 K-66.2 K
Operating Income-16.3 M-17.1 M
Net Loss-12.9 M-13.6 M
Income Before Tax-15.7 M-16.5 M
Total Other Income Expense Net544 K571.2 K
Net Loss-24.6 M-25.8 M
Net Loss-15.7 M-16.5 M
Income Tax Expense928 K974.4 K
Interest Income442 K321.5 K
Net Interest Income442 K365.4 K
Non Operating Income Net Other-594.9 K-624.6 K
Change To Netincome2.2 M1.7 M
Net Loss(3.42)(3.59)
Income Quality 1.26  1.32 
Net Income Per E B T 0.89  0.67 

Aileron Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Aileron Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aileron Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aileron Therapeutics' important profitability drivers and their relationship over time.

Use Aileron Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aileron Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Aileron Therapeutics Pair Trading

Aileron Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Aileron Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aileron Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aileron Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aileron Therapeutics to buy it.
The correlation of Aileron Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aileron Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aileron Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aileron Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Aileron Therapeutics position

In addition to having Aileron Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Penny Thematic Idea Now

Penny
Penny Theme
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Aileron Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aileron Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aileron Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aileron Therapeutics Stock:
Check out Trending Equities.
To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
To fully project Aileron Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Aileron Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Aileron Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Aileron Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Aileron Therapeutics investors may work on each financial statement separately, they are all related. The changes in Aileron Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aileron Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.